Jpmorgan Chase & CO Emergent Bio Solutions Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 22,428 shares of EBS stock, worth $226,747. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,428
Previous 22,428
-0.0%
Holding current value
$226,747
Previous $197,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding EBS
# of Institutions
191Shares Held
41.3MCall Options Held
899KPut Options Held
256K-
Black Rock Inc. New York, NY3.84MShares$38.8 Million0.0% of portfolio
-
Oak Hill Advisors LP New York, NY3.61MShares$36.5 Million3.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.54MShares$35.8 Million0.0% of portfolio
-
State Street Corp Boston, MA2.45MShares$24.7 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO2.38MShares$24.1 Million0.01% of portfolio
About Emergent BioSolutions Inc.
- Ticker EBS
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 49,861,500
- Market Cap $504M
- Description
- Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...